Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 8:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–43 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: ipratropium bromide Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Ipratropium on Acute Bronchitis in Subjects Without Underlying Lung Disease

NCT00371527
View directory record Official record
Conditions
Bronchitis
Interventions
ipratropium
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2008 · Synced Sep 29, 2026, 8:05 PM EDT
Completed Phase 3 Interventional

A Crossover Study in the Treatment of Patients With COPD

NCT00462540
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Formoterol Fumurate inhalation solution 20 mcg, Ipratropium bromide 18 mcg and albuterol sulfate 103 mcg
Drug
Lead sponsor
Dey
Industry
Eligibility
40 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
15
States / cities
San Diego, California • Denver, Colorado • Wheat Ridge, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2009 · Synced Sep 29, 2026, 8:05 PM EDT
Completed Phase 4 Interventional Results available

Effect of Nebulized Bronchodilators on Heart Rate

NCT01151579
View directory record Official record
Conditions
COPD, Sepsis, Shock
Interventions
Levalbuterol, Albuterol
Drug
Lead sponsor
Fahim Khorfan, MD
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Grand Blanc, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 22, 2015 · Synced Sep 29, 2026, 8:05 PM EDT
Completed Not applicable Interventional

Evaluation of Breathing Pattern and Dyspnea in Subjects With Tetraplegia

NCT00904436
View directory record Official record
Conditions
Dyspnea, Tetraplegia
Interventions
ipratropium (Atrovent)
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2009 · Synced Sep 29, 2026, 8:05 PM EDT
Completed Phase 4 Interventional Results available

Budesonide Inhalation Suspension for Acute Asthma in Children

NCT00393367
View directory record Official record
Conditions
Asthma, Acute Asthma, Reactive Airway Exacerbation
Interventions
Budesonide inhalation suspension (0.5 mg/2mL) 2mg, albuterol (5mg/mL) 7.5 or 10mg, Prednisolone, prednisone, or methylprednisolone, Albuterol, ipratropium bromide, Ipratropium bromide
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Years to 18 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 9, 2012 · Synced Sep 29, 2026, 8:05 PM EDT
Completed Phase 2 Interventional

Revefenacin in Acute Respiratory Insufficiency in COPD

NCT04315558
View directory record Official record
Conditions
COPD, Acute Respiratory Failure
Interventions
Revefenacin Inhalation Solution [Yupelri], Ipratropium Bromide
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
40 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Los Angeles, California • Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Sep 29, 2026, 8:05 PM EDT
Completed Phase 4 Interventional Results available

A Study to Look at Day to Day Changes in Lung Function in COPD Subjects Taking Albuterol/Salbutamol and Ipratropium

NCT01691482
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Albuterol/salbutamol, Ipratropium
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Sep 29, 2026, 8:05 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

An Efficacy and Safety Profile of Inhaled TV48108 in Healthy Volunteers and COPD Patients

NCT02315144
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
TV48108, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
20 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
2
States / cities
Medford, Oregon • Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 29, 2026, 8:05 PM EDT
Completed Not applicable Interventional Results available

A Comparison of Levalbuterol Plus Ipratropium With Levalbuterol Alone in the Treatment of Acute Asthma Exacerbation

NCT00583778
View directory record Official record
Conditions
Asthma
Interventions
ipratropium
Drug
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years to 45 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 15, 2022 · Synced Sep 29, 2026, 8:05 PM EDT
Completed Phase 2 Interventional Results available

Treating Respiratory Emergencies in Children Study

NCT06074185
View directory record Official record
Conditions
Asthma in Children
Interventions
Ipratropium Bromide
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
2 Years to 17 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Buffalo, New York • Charlotte, North Carolina • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 29, 2026, 8:05 PM EDT
Withdrawn Phase 2 Interventional

Non Invasive Positive Pressure Ventilation in Status Asthmaticus

NCT01403428
View directory record Official record
Conditions
Status Asthmaticus
Interventions
Noninvasive positive pressure ventilation
Other
Lead sponsor
Southern Illinois University
Other
Eligibility
1 Year to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 11, 2014 · Synced Sep 29, 2026, 8:05 PM EDT
Completed Phase 3 Interventional

12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD

NCT00240435
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler, 10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler
Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
14
States / cities
Birmingham, Alabama • Downey, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Sep 29, 2026, 8:05 PM EDT
Completed Phase 4 Interventional

Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.

NCT00388882
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium, ipratropium bromide / albuterol
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
10
States / cities
Phoenix, Arizona • Lakewood, California • Sepulveda, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Sep 29, 2026, 8:05 PM EDT
Completed Phase 2 Interventional Results available

4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma

NCT00818454
View directory record Official record
Conditions
Asthma
Interventions
Combivent CFC MDI, Albuterol HFA MDI, Respimat Combivent
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
41
States / cities
Birmingham, Alabama • Los Angeles, California • Palmdale, California + 36 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Sep 29, 2026, 8:05 PM EDT
Completed No phase listed Observational Results available

Pharmacogenetics of b2-Agonists in Asthma.

NCT00708227
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
10 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 21, 2018 · Synced Sep 29, 2026, 8:05 PM EDT
Completed Phase 3 Interventional Results available

The Effects Of Bronchodilator Therapy On Respiratory And Autonomic Function In Patients With Familial Dysautonomia

NCT01987219
View directory record Official record
Conditions
Familial Dysautonomia
Interventions
Albuterol-sulphate, Ipratropium-bromide, placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
12 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2016 · Synced Sep 29, 2026, 8:05 PM EDT
Terminated Phase 4 Interventional Results available

Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)

NCT03219866
View directory record Official record
Conditions
COPD, COPD Exacerbation
Interventions
Nebulizers, Dry Powder Inhaler, Brovana, Pulmicort, Atrovent, Advair Diskus, Spiriva HandiHaler
Device · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Sep 29, 2026, 8:05 PM EDT
Terminated Phase 2 Interventional Results available

A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmonary Disease (COPD)

NCT03170232
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Danirixin 35 mg tablets, Placebo, Metered dose inhaler (MDI) sensor device, Rescue medication
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 76 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
11
States / cities
Birmingham, Alabama • San Diego, California • Torrance, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Sep 29, 2026, 8:05 PM EDT
Completed Phase 2 Interventional Results available

Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101(SUN101) in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study

NCT01426009
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
EP-101 via nebulizer (eFlow®) 25 ug, EP-101 via nebulizer (eFlow®) 50 ug, EP-101 via nebulizer (eFlow®) 100 ug, Placebo EP-101, Tiotropium bromide via (Spiriva® Handihaler®), Ipratropium bromide Inhalation Solution via Handihaler® DPI, EP-101 via nebulizer (eFlow®) 200 ug
Drug
Lead sponsor
Sunovion Respiratory Development Inc.
Industry
Eligibility
40 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • DeLand, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Sep 29, 2026, 8:05 PM EDT